Category: FDA Personalized Medicine Pharmaceutical Industry Videos patient-centered healthcare Janet Woodcock Frank Torti Renata Reimschuessel CDRH CVM CDER
Submitted by pharmamanufacturing on Wed, 10/21/2009 - 18:19
Last year, I attended FDA’s first science writers’ symposium, an interesting program that I’m looking forward to again this year. I wrote up a brief report on the event and took some very amateur videos of scientists’ presentations, envisioning the construction of some grand documentary on FDA's new lab...
Category: management human resources Common sense Lean Six Sigma and Quality Improvement The Pharma Industry Peter Rost Pfizer Personalized Medicine Pharma Workforce and Staffing Pharmaceutical Mergers and Acquisitions Wyeth
Submitted by pharmamanufacturing on Fri, 01/23/2009 - 11:58
The blockbuster model is dying a very slow and painful death and there will be more collateral damage before it's all over. Early morning brought news that Pfizer might buy Wyeth Pharmaceuticals, including its biologics division, for $60 billion.
Category: The Pharma Industry Personalized Medicine New Drug Pipeline and R&D Information Technology and Software Pharmaceutical Patents and Intellectual Property Pharmaceutical Industry CEOs Pharmaceutical Industry Goodwill and Philanthropy Environmental issues and green pharma Supply Chain Management management Drug pricing drug development DIA IBM Life Sciences patient-centered healthcare pandemic monitoring and surveillance Mike Svinte
Submitted by pharmamanufacturing on Wed, 06/25/2008 - 11:11
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
Submitted by pharmamanufacturing on Tue, 05/29/2007 - 14:30
Recent posts on leading pharma industry blogs, including Derek Lowe's In the Pipeline and John Mack's Pharma Marketing Blog, have responded to a post on the Healthcare Renewal blog discussing safety and marketing issues with GSK's diabetes drug Avandia.